Schwab Charles Investment Management Inc. grew its stake in Healthequity Inc (NASDAQ:HQY) by 13.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 225,389 shares of the company’s stock after buying an additional 27,073 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.37% of Healthequity worth $11,401,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Healthequity by 3.0% in the 2nd quarter. Vanguard Group Inc. now owns 4,237,298 shares of the company’s stock valued at $211,145,000 after purchasing an additional 122,061 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Healthequity by 25.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 473,433 shares of the company’s stock valued at $23,591,000 after purchasing an additional 95,514 shares in the last quarter. First Trust Advisors LP increased its stake in shares of Healthequity by 17.0% in the 2nd quarter. First Trust Advisors LP now owns 94,283 shares of the company’s stock valued at $4,698,000 after purchasing an additional 13,676 shares in the last quarter. Fred Alger Management Inc. increased its stake in shares of Healthequity by 30.4% in the 2nd quarter. Fred Alger Management Inc. now owns 265,369 shares of the company’s stock valued at $13,223,000 after purchasing an additional 61,880 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Healthequity by 12.7% in the 2nd quarter. Legal & General Group Plc now owns 87,541 shares of the company’s stock valued at $4,360,000 after purchasing an additional 9,858 shares in the last quarter. 98.27% of the stock is owned by institutional investors and hedge funds.

Several research firms have commented on HQY. BidaskClub upgraded Healthequity from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. Zacks Investment Research upgraded Healthequity from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research note on Wednesday, October 11th. Robert W. Baird reiterated a “hold” rating on shares of Healthequity in a research note on Thursday, September 21st. Cantor Fitzgerald reiterated a “buy” rating and set a $56.00 price objective on shares of Healthequity in a research note on Tuesday, December 5th. Finally, Chardan Capital boosted their price objective on Healthequity from $58.00 to $62.00 and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Healthequity has a consensus rating of “Buy” and a consensus price target of $58.33.

In other news, Director Frank Medici sold 700 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $51.05, for a total transaction of $35,735.00. Following the transaction, the director now directly owns 6,381 shares in the company, valued at approximately $325,750.05. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Delano Ladd sold 26,405 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $43.32, for a total value of $1,143,864.60. Following the transaction, the executive vice president now owns 16,692 shares in the company, valued at $723,097.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,761,117 shares of company stock worth $91,915,316. Insiders own 19.00% of the company’s stock.

Shares of Healthequity Inc (NASDAQ:HQY) opened at $48.21 on Thursday. Healthequity Inc has a 52 week low of $37.62 and a 52 week high of $55.31. The company has a market capitalization of $2,960.00, a P/E ratio of 65.15, a price-to-earnings-growth ratio of 2.01 and a beta of 1.74.

Healthequity (NASDAQ:HQY) last issued its earnings results on Tuesday, December 5th. The company reported $0.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.04. The business had revenue of $56.80 million for the quarter, compared to analysts’ expectations of $55.27 million. Healthequity had a return on equity of 14.47% and a net margin of 21.08%. The business’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 EPS. analysts expect that Healthequity Inc will post 0.71 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Schwab Charles Investment Management Inc. Has $11.40 Million Stake in Healthequity Inc (HQY)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/schwab-charles-investment-management-inc-has-11-40-million-stake-in-healthequity-inc-hqy/1785893.html.

Healthequity Company Profile

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Healthequity Inc (NASDAQ:HQY).

Institutional Ownership by Quarter for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with Analyst Ratings Network's FREE daily email newsletter.